Eve Barys/LinkedIn
May 7, 2026, 15:34
Eve Barys: What’s New – Thrombosis in Immune Thrombocytopenia
Eve Barys, Sr. Strategic Account Executive at Wolters Kluwer Health, shared a post on LinkedIn:
“Immune thrombocytopenia (ITP) is generally associated with bleeding, but individuals with ITP can also develop thrombosis.
A study of ITP documented venous thrombosis in about 4 percent of patients.
Features associated with thrombosis included older age, prior thrombosis, secondary ITP, and use of a thrombopoietin receptor agonist.
Management with anticoagulation is appropriate, and some individuals may require more intensive ITP therapies to raise the platelet count and allow for full anticoagulation.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 22:47Avirup Guha: Early Immune Responses to Androgen Deprivation Therapy and Coronary Plaque Progression
-
Nov 9, 2026, 22:42Angela Forsyth: Joining Novo Nordisk as Medical Liaison for the Ohio Valley Region
-
Nov 9, 2026, 22:36Vladimir Otasevic: Presenting Thromboprophylaxis and Treatment of VTE in Patients With Malignancy
-
Nov 9, 2026, 22:28Dragoș Claudiu Popescu: Corticosteroid Exposure and Thrombotic Risk in ITP
-
Nov 9, 2026, 22:20Cedric Ghevaert: How RNA Processing Defects Affect Megakaryocytes in TAR Syndrome
-
Nov 9, 2026, 22:07Todd C. Villines: PARAMOUNT Shows Benefits of Coronary Plaque-Based Care in Stable Symptomatic Patients
-
Nov 9, 2026, 22:06Maxima Mendez: Complete Results of the Pelacarsen Cardiovascular Outcomes Study at AHA 2026
-
Nov 9, 2026, 22:04The Role of the Spleen in Inflammation During Acute Plasmodium Vivax Malaria – American Journal of Hematology
-
Nov 9, 2026, 21:52Behnood Bikdeli: Honored to Share the Stage at AHA 2026 to Discuss Grant Funding